AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway
Chen Liu,Yuhan Huang,Tianyu Qin,Lixin You,Funian Lu,Dianxing Hu,Rourou Xiao,Xu Qin,Ensong Guo,Bin Yang,Xi Li,Junpeng Fan,Xiong Li,Yu Fu,Si Liu,Zhuozi Wang,Yingyu Dou,Wei Wang,Wenting Li,Xiaohang Yang,Jingbo Liu,Wenju Peng,Li Zhang,Yaoyuan Cui,Chaoyang Sun,Gang Chen
DOI: https://doi.org/10.1016/j.canlet.2021.12.021
IF: 9.756
2022-03-01
Cancer Letters
Abstract:The CDK4/6 inhibitor, palbociclib has recently entered clinic-trial stage for breast cancer treatment. However, translating its efficacy to other solid tumors has been challenging, especially for aggressive solid tumors. We found that the effect of palbociclib as a single agent was limited due to primary and acquired resistance in multiple ovarian cancer (OC) models. Among these, patient-derived organoid and xenograft models are two most representative models of drug responsiveness in patients with OC. In preclinical models, this study demonstrated that activated MAPK/PI3K-AKT pathway and cell cycle-related proteins induced the resistance to palbociclib, which was overcome by the addition of the bromodomain protein 4 (BRD4) inhibitor AZD5153. Moreover, this study revealed that AZD5153 and palbociclib had a synergistic lethal effect on inducing the cell cycle arrest and increasing apoptosis, even in RB-deficient cell lines. Based on these results, it is anticipated that this class of drugs, including AZD5153, which inhibit the cell cycle-related protein and MAPK/PI3K-AKT pathway, will exhibit synergistic effects with palbociclib in OC.
oncology